newsfilter
← Latest News
Business Wire·

QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook

Sample technologies, QIAcuity and QDI deliver solid growth; QuantiFERON sales affected by significantly lower immigration testing demand QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced